446P - Accuracy of risk scoring system to determine chemotherapy induced nausea and vomiting (CINV) in cancer patients receiving first cycle chemotherapy

Background

Evaluation of the risk scoring algorithm to identify patient based risk factors associated with increased risk for CINV.

Methods

Patients who were receiving first chemotherapy regime at our center were included in the study after due informed consenting and Ethics committee approval. Patients were followed for 5-days after chemotherapy by either in person questioning or telephone call. All patients received standard anti-emetic prophylaxis at discretion of treating physician. Before each cycle of chemotherapy, acute and delayed CINV scoring systems were used to stratify patients into low- and high-risk groups. Logistic regression modelling was then applied to compare the risk for grade 2 or greater CINV between patients considered to be at high and at low risk. The external validity of each system was also assessed using an area under the receiver operating characteristic curve (AUROC) analysis.

Results

CINV outcomes data was collected from 127 patients at 1^st cycle of chemotherapy. The incidence of acute and delayed CINV was 42.7% and 76.4% respectively. Major predictors for CINV included younger patient age, platinum- or anthracycline based chemotherapy, low alcohol consumption, earlier cycles of chemotherapy, previous history of morning sickness, and prior emetic episodes after chemotherapy. The acute and delayed scoring systems both had good predictive accuracy when applied to the external validation sample (acute— AUROC: 0.70; 95% confidence interval: 0.60 to 0.80; delayed—AUROC: 0.70; 95% confidence interval: 0.61 to 0.80). Patients identified by the scoring systems to be at high risk were 1.3 (p = 0.001) and 2.3 (p = 0.001) times more likely to develop grade 2 or greater acute and delayed CINV.

Conclusions

Our study demonstrates current Patient risk scoring systems are able to accurately identify patients at high risk for delayed CINV and can be used to augment current antiemetic regimes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Vinayak V Maka.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.